Hematology · Medical Literature
All-Trans Retinoic Acid for Immune Thrombocytopenia - Sustained Response?
Clinical relevance
This NEJM Evidence editorial contextualizes a contemporaneous randomized trial (Zhang et al., NEJM Evidence 2026; DOI: 10.1056/EVIDoa2500333) evaluating ATRA plus eltrombopag for refractory/relapsed immune thrombocytopenia (ITP) — a population with few disease-modifying options and a high burden of chronic thrombocytopenia-related bleeding. Current standard agents such as thrombopoietin receptor agonists (TPO-RAs) and rituximab improve platelet counts but do not correct the underlying immunological defect, and responses are frequently non-sustained. ATRA, a repurposed oral vitamin A derivative with established immunomodulatory and thrombopoiesis-promoting mechanisms, offers a potentially affordable strategy to induce durable remission in patients who have failed or relapsed after corticosteroids and other second-line therapies. NOTE: Full quantitative results from this specific trial are not publicly available; the following findings are drawn from the best available contextual evidence from the same research group and closely related published trials.
Key findings
1. COMBINATION ATRA + TPO-RA RATIONALE (trial context): The NEJM Evidence original article (Zhang et al., 2026) evaluates ATRA plus eltrombopag vs. eltrombopag monotherapy in steroid-resistant/relapsed ITP, directly extending prior work showing ATRA augments sustained response when added to standard agents. 2. ATRA + LOW-DOSE RITUXIMAB (prior phase 2 RCT, n=168): Overall response rate was 80% (90/112) with ATRA plus rituximab vs. 59% (33/56) with rituximab monotherapy (between-group difference 0.22; 95% CI 0.07–0.36); sustained response rate was 61% vs. 41%, respectively. 3. ATRA + HIGH-DOSE DEXAMETHASONE (first-line phase 2 RCT): The combination achieved a 68.2% 6-month sustained response (platelet count >50 × 10⁹/L without additional ITP-modifying therapy) vs. 41% with dexamethasone alone. 4. META-ANALYSIS ACROSS 4 RCTs (n=760 patients): Pooled OR for sustained response with ATRA-containing regimens vs. comparators was 3.00 (95% CI 1.97–4.57; P<0.01); OR for overall response rate was 3.21 (95% CI 2.15–4.78; P<0.01); OR for complete response rate was 2.12 (95% CI 1.17–3.86; P=0.01). 5. RELAPSE AND SALVAGE RATE REDUCTION: ATRA was associated with significant reductions in both relapse rate (OR 0.30; 95% CI 0.18–0.50; P<0.01) and requirement for salvage therapy (OR 0.36; 95% CI 0.23–0.56; P<0.01) compared to control arms. 6. SAFETY PROFILE: The predominant grade 1–2 adverse events attributable to ATRA were dry skin (pooled OR 49.99; 95% CI 16.05–155.67; P<0.01), headache/dizziness (OR 1.75; 95% CI 0.98–3.12; P=0.06), and acneiform rash (OR 0.37; 95% CI 0.10–1.34; P=0.13); no grade 3–4 ATRA-specific toxicities were consistently reported across trials. NOTE: trial-specific quantitative data from the NEJM Evidence 2026 publication are not yet publicly accessible; figures above are from the closest related evidence base.
Practice implications
Hematologists managing adults with corticosteroid-resistant or relapsed ITP should consider ATRA (typically 10–20 mg/m² orally twice daily for 12 weeks) as an add-on to existing second-line agents — particularly eltrombopag or rituximab — given consistent data showing a two- to three-fold improvement in sustained response rates over monotherapy without significant grade ≥3 toxicity. Patient selection should prioritize those who have failed at least one prior non-corticosteroid therapy, have no contraindication to retinoids (e.g., active hepatic disease, pregnancy, or teratogenicity risk in women of childbearing potential requiring strict contraception), and for whom disease-modifying rather than purely platelet-supportive therapy is the goal. Monitoring should include liver function tests, lipid panels, and mucocutaneous adverse effects at baseline and during therapy, with dose adjustment guided by tolerability; the oral, low-cost nature of ATRA makes it a particularly actionable option in resource-limited settings where biologic therapies are inaccessible.